53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma

• Published in: BMC cancer 2013-03, Vol.13 (1), p.155-155, Article 155
• Main Authors: Ausborn, Natalie L, Wang, Tong, Wentz, Sabrina C, Washington, Mary Kay, Merchant, Nipun B, Zhao, Zhiguo, Shyr, Yu, Chakravarthy, Anuradha Bapsi, Xia, Fen
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma - blood; Adenocarcinoma - secondary; Adenocarcinoma - surgery; Aged; Analysis; Antibodies; Breast cancer; CA-19-9 Antigen - blood; DNA damage; DNA repair; Female; Gene expression; Genetic research; Humans; Intracellular Signaling Peptides and Proteins - metabolism; Ionizing radiation; Kaplan-Meier Estimate; Lymph Nodes - pathology; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Pancreatic Neoplasms - blood; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - surgery; Prognosis; Proportional Hazards Models; Proteins; Tissue Array Analysis; Tumor Suppressor p53-Binding Protein 1; Tumors; Viral antibodies
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-13-155

53BP1 binds to the tumor suppressor p53 and has a key role in DNA damage response and repair. Low 53BP1 expression has been associated with decreased survival in breast cancer and has been shown to interact with several prognostic factors in non-small cell lung cancer. The role of 53BP1 in pancreatic ductal adenocarcinoma (PDAC) has yet to be determined. We aimed to investigate whether 53BP1 levels interact with established prognostic factors in PDAC. 106 patients for whom there was tissue available at time of surgical resection for PDAC were included. A tissue microarray was constructed using surgical specimens, stained with antibodies to 53BP1, and scored for expression intensity. Univariate and multivariate statistical analyses were performed to investigate the association between 53BP1 and patient survival with known prognostic factors for survival. The association of 53BP1 with several established prognostic factors was examined, including stage, tumor grade, surgical margin, peripancreatic extension, lymph node ratio (LNR), and CA 19-9. We found that 53BP1 modified the effects of known prognostic variables including LNR and CA 19-9 on survival outcomes. When 53BP1 intensity was low, increased LNR was associated with decreased OS (HR 4.84, 95% CI (2.26, 10.37), p